Welcome to our dedicated page for Sotera Health Company news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health Company stock.
Sotera Health Company (Nasdaq: SHC) is a leading global provider of sterilization, lab testing, and advisory services, primarily serving the medical device, pharmaceutical, and food industries. The company operates through three main segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics offers terminal sterilization and irradiation services, including gamma and electron beam irradiation, and EO processing. Nordion supplies Co-60 and gamma irradiators, which are critical for the gamma sterilization process. Nelson Labs specializes in outsourced microbiological and analytical chemistry testing.
The company is known for its commitment to ensuring the safety and quality of healthcare products through its comprehensive suite of services. Sotera Health’s lab services cover analytical chemistry, medical device testing, pharmaceutical lab testing, and microbiology testing, helping clients identify and mitigate risks. The advisory segment supports clients in navigating regulatory requirements throughout the product lifecycle.
Recently, Sotera Health has achieved significant milestones, including a 6.7% increase in net revenues for its Sterigenics segment in Q3 2023, driven by favorable pricing and currency exchange rates. Nordion reported a 14.3% increase in net revenues, reflecting robust demand for its services.
Despite challenges, the company has shown resilience, evidenced by a 5.8% increase in third-quarter 2023 net revenues to $263 million. However, a net loss of $14 million was reported due to a $35 million legal settlement. Sotera Health’s ongoing projects include expanding its service offerings and enhancing operational efficiencies.
Headquartered in Cleveland, Ohio, the company had $2.3 billion in total debt and $245 million in cash equivalents as of September 30, 2023, reflecting a strong financial position to support its strategic initiatives. The company continues to focus on its mission of 'Safeguarding Global Health®.'
Firstlight Management LP, a shareholder of Sotera Health Company (SHC), has sent a letter to the Board of Directors urging the sale of its Nelson Labs subsidiary. The investment firm argues that Nelson Labs has underperformed with a mere 2.7% EBITDA CAGR over 2018-2024E, significantly lower than Sterigenics (9.8%) and Nordion (8.2%). The proposed sale could generate approximately $1.1bn in gross proceeds at a 15.2x EBITDA multiple, potentially reducing SHC's net leverage ratio from 3.7x to 2.2x on 2024E EBITDA. The transaction could result in ~13% lift to 2025E EPS and allow management to focus on core sterilization businesses.
Sotera Health Company (Nasdaq: SHC) announced its 2024 Investor Day in New York City, where management will present the company's strategic positioning and future growth plans. The company, which provides sterilization solutions and lab testing services, will outline its 2025-2027 financial plan targeting 5-7% organic revenue growth, 5-8% Adjusted EBITDA growth, and over $500 million in cumulative Free Cash Flow. Management will discuss their $18 billion serviceable addressable market and demonstrate the company's strength while fulfilling its Safeguarding Global Health® mission.
Sotera Health (SHC) reported strong Q3 2024 financial results with net revenues increasing 8.5% to $285 million. The company achieved net income of $17 million ($0.06 per diluted share), compared to a net loss of $14 million in Q3 2023. Adjusted EBITDA grew 9.0% to $146 million.
Year-to-date performance showed net revenues up 9.6% to $810 million, with net income of $32 million. All three business segments - Sterigenics, Nordion, and Nelson Labs - reported revenue growth. The company reaffirmed its 2024 outlook for net revenues and Adjusted EBITDA growth of 4.0% to 6.0%.
Sotera Health Company (Nasdaq: SHC), a leading global provider of sterilization solutions and lab testing services for the healthcare industry, has announced key dates for investors:
1. Third-Quarter 2024 Earnings Release: Financial results will be released on November 5, 2024, before market open. A conference call will follow at 9:00 a.m. Eastern Time.
2. Inaugural Investor Day: Scheduled for November 20, 2024, at 12:30 p.m. Eastern Time in New York City. The event will feature presentations by management and a Q&A session.
Both events will be accessible via webcast through the company's Investor Relations website. Dial-in numbers for the earnings call and pre-registration links for the Investor Day webcast are provided. Replays and presentation materials will be available on the company's website following the events.
Sotera Health Company (Nasdaq: SHC) has announced a secondary offering of 25,000,000 shares of its common stock. The shares are being sold by affiliates of Warburg Pincus and GTCR , not by the company itself. As a result of this offering, Sotera Health's sponsors are expected to lose their majority ownership, affecting certain sponsor rights. Citigroup is acting as the underwriter for the offering, which will be conducted through various transactions on Nasdaq, over-the-counter, or through negotiated deals. Sotera Health will not receive any proceeds from the offering but will cover the expenses as per its Amended and Restated Registration Rights Agreement.
Sotera Health Company (Nasdaq: SHC) reported its Q2 2024 financial results, showing 8.3% growth in net revenues to $277 million. However, net income decreased to $9 million ($0.03 per diluted share) from $24 million ($0.08 per diluted share) in Q2 2023, primarily due to debt refinancing charges. Adjusted EBITDA increased by 6.9% to $137 million, while Adjusted EPS slightly declined to $0.19.
For the first half of 2024, net revenues increased by 10.3% to $525 million, with Adjusted EBITDA up 9.8% to $249 million. The company successfully refinanced its debt structure, extending maturities to 2031. Sotera Health reaffirmed its 2024 outlook, projecting 4-6% growth in net revenues and Adjusted EBITDA.
Sotera Health Company (Nasdaq: SHC) has appointed Christopher Simon as a new independent director to its Board of Directors. Simon will serve on the Leadership Development and Compensation Committee. He brings over 30 years of experience in business transformation and growth, currently serving as President and CEO of Haemonetics (NYSE: HAE). Simon's background includes roles at McKinsey & Company, Baxter Healthcare , and as a U.S. Army Infantry Officer.
Michael B. Petras, Jr., Chairman and CEO of Sotera Health, expressed excitement about Simon's addition, citing his leadership experience as a public company CEO and extensive commercial and strategic expertise in the life sciences industry as valuable assets for the company's growth. Simon also serves on the board of directors of AdvaMed, a global medical technology trade association.
Sotera Health Company (Nasdaq: SHC), a leading global provider of sterilization solutions and lab testing services for the healthcare industry, has announced its plans to release second-quarter 2024 financial results on Monday, August 5, 2024, before the market opens. The company will hold a conference call at 9:00 a.m. Eastern Time to discuss operating highlights and financial results.
To participate in the live call, investors can dial 1-844-481-2916 from the United States or 1-412-317-0709 from other locations. A live webcast of the conference call will be available on the company's website, along with accompanying materials. A replay of the webcast will be available later on the same day.
Sotera Health (Nasdaq: SHC) has announced the successful closing of a $1.51 billion Term Loan B and $750 million in senior secured notes, both maturing in 2031. The company will use the proceeds to refinance its existing $1.76 billion and $496.3 million Term Loan B facilities. This refinancing is expected to save approximately $5 million in interest expenses for 2024, reducing the projected interest expense to $165-175 million. Term Loan B offers a variable interest rate with options for SOFR-based or alternate base rate loans, and is prepayable without penalties after six months. The senior secured notes carry an interest rate of 7.375% per annum, payable semi-annually. This move is seen as favorable and reflects the market's confidence in Sotera Health's business strength.
Sotera Health reported positive financial results for the first quarter of 2024, with a 12.5% increase in net revenues to $248 million compared to the same period in 2023. Net income also saw a significant improvement, reaching $6 million or $0.02 per diluted share. Adjusted EBITDA increased by 13.7% to $112 million, and Adjusted EPS remained steady at $0.13. The company reaffirmed its 2024 outlook, anticipating continued growth and navigating market challenges.
FAQ
What is the current stock price of Sotera Health Company (SHC)?
What is the market cap of Sotera Health Company (SHC)?
What services does Sotera Health Company offer?
What are the main segments of Sotera Health?
How did Sotera Health perform in the third quarter of 2023?
What are the key components of the gamma sterilization process provided by Nordion?
What financial condition is Sotera Health in as of September 30, 2023?
What recent achievements has Sotera Health made?
Where is Sotera Health headquartered?
What is the company’s mission?
What are Sotera Health’s advisory services focused on?
What recent financial results did Sotera Health announce?
